Table 4.
Correlations of CVD risk factors, sex hormone concentrations, and inflammatory and oxidative stress markers with brachial artery FMD and RHI in the pooled cohort
| Variables | Brachial artery FMD | RHI | Total testosterone | Free testosterone | ||||
|---|---|---|---|---|---|---|---|---|
| r | P | r | P | r | P | r | P | |
| Age, yr | -0.47 | <0.001 | 0.40 | 0.002 | -0.22 | 0.097 | -0.54 | <0.001 |
| Seated SBP, mmHg | -0.44 | <0.001 | 0.11 | 0.432 | -0.24 | 0.069 | -0.38 | 0.003 |
| BMI, kg/m2 | -0.33 | 0.012 | 0.25 | 0.068 | -0.39 | 0.002 | -0.33 | 0.012 |
| Total body fat, % | -0.22 | 0.100 | 0.17 | 0.221 | -0.30 | 0.020 | -0.30 | 0.019 |
| Waist circumference, cm | -0.40 | 0.002 | 0.17 | 0.209 | -0.33 | 0.010 | -0.33 | 0.011 |
| WHR | -0.22 | 0.102 | 0.01 | 0.999 | 0.142 | 0.282 | 0.02 | 0.872 |
| Total cholesterol, mg/dL | 0.02 | 0.890 | 0.03 | 0.813 | -0.02 | 0.883 | -0.12 | 0.348 |
| LDL-cholesterol, mg/dL | 0.03 | 0.827 | 0.05 | 0.733 | -0.4 | 0.782 | -0.15 | 0.250 |
| Triglycerides, mg/dLa | -0.05 | 0.773 | 0.05 | 0.691 | -0.39 | 0.002 | -0.37 | 0.004 |
| Glucose, mg/dL | -0.39 | 0.003 | 0.09 | 0.493 | -0.23 | 0.075 | -0.22 | 0.090 |
| Insulin, uIU/mLa | -0.10 | 0.463 | 0.01 | 0.948 | -0.26 | 0.046 | -0.05 | 0.702 |
| HOMA-IRa | -0.18 | 0.176 | 0.04 | 0.759 | -0.28 | 0.035 | -0.08 | 0.563 |
| Total testosterone, ng/dL | 0.45 | <0.001 | -0.15 | 0.272 | 1 | - | 0.72 | <0.001 |
| Free testosterone, ng/dL | 0.40 | 0.002 | -0.36 | 0.006 | 0.72 | <0.001 | 1 | - |
| Estradiol, pg/mL | -0.11 | 0.394 | 0.07 | 0.601 | 0.39 | 0.002 | 0.01 | 0.937 |
| SHBG, nmol/L | 0.11 | 0.401 | 0.18 | 0.176 | 0.56 | <0.001 | -0.16 | 0.234 |
| LH, mIU/mL | 0.09 | 0.489 | 0.20 | 0.143 | 0.06 | 0.681 | -0.11 | 0.417 |
| FSH, mIU/mL | -0.6 | 0.663 | 0.29 | 0.034 | -0.24 | 0.069 | -0.28 | 0.034 |
| V̇O2peak, mL/min/kg | 0.38 | 0.005 | -0.24 | 0.078 | 0.37 | 0.004 | -0.48 | <0.001 |
| WBC | -0.14 | 0.309 | -0.09 | 0.515 | -0.30 | 0.022 | -0.11 | 0.426 |
| IL-6, pg/mLa | -0.50 | <0.001 | 0.27 | 0.047 | -0.44 | 0.001 | -0.53 | <0.001 |
| CRP, mg/La | -0.38 | 0.004 | 0.07 | 0.607 | -0.44 | <0.001 | -0.44 | <0.001 |
| TAS, mmol/L | -0.03 | 0.821 | -0.20 | 0.143 | -0.19 | 0.159 | 0.08 | 0.563 |
| Oxidized LDL-cholesterol, U/L | 0.13 | 0.332 | -0.07 | 0.592 | 0.19 | 0.165 | 0.10 | 0.469 |
| FRS | -0.34 | 0.010 | 0.47 | >0.001 | -0.21 | 0.116 | -0.54 | <0.001 |
| qADAM score | 0.02 | 0.357 | -0.06 | 0.660 | 0.27 | 0.042 | 0.19 | 0.152 |
| AMS scorea | -0.14 | 0.316 | 0.34 | 0.013 | -0.30 | 0.027 | -0.26 | 0.058 |
Bold font indicates significant correlation.
Abbreviations: AMS, aging male symptom scale; BMI, body mass index; CRP, C-reactive protein; FMD, flow-mediated dilation; FRS, Framingham Risk Score; FSH, follicle-stimulating hormone; HOMA-IR, homeostatic model assessment of insulin resistance; IL-6, interleukin-6; LDL, low-density lipoprotein; LH, luteinizing hormone; qADAM, quantitative androgen deficiency in the again male questionnaire; SBP, systolic blood pressure; SHBG, sex hormone binding globulin; TAS, total antioxidant status; WHR, waist-hip ratio; WBC, white blood count.
anon-parametric data analyzed using Spearman correlations.